CALCISCON AG

Company founded: August 2013

CALCISCO develops and commercializes the very first and only diagnostic blood test available for the determination of calcification risk/propensity in serum (Pasch et al., JASN, 2012; “T50 test”). The main product will be a diagnostic test kit sold and distributed to clinical laboratories. The first target group to benefit from the T50 test is chronic kidney disease (CKD) patients.
A research test service is already established and currently offered mainly for clinical studies; the diagnostic test kit will follow.
In the long-term, extension to the general cardiovascular field is envisaged, and novel treatment options to reduce calcification risk shall be developed.

Milestones / News

Funding Activity 23.03.2015

Series A

Funding Activity

seed financing

Documents

Videos and Presentations

Video 1

>

CALCISCON AG

Matthias Meier

Seidenweg 12
3012 Bern

http://www.calciscon.com

Contact

Sharing

PARTNERS